Uniplasty Inc (UPI) Thursday highlighted the results of a study that compared the cost effectiveness of neuromodulation therapies for Overactive Bladder (OAB) patients over two years of treatment.
The medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions stated that the study compared percutaneous tibial nerve stimulation delivered via Uroplasty's Urgent PC Neuromodulation System versus sacral nerve stimulation.
Melissa Martinson, PhD, lead author of the study stated, "This study demonstrates significant cost savings to the healthcare system when PTNS is used instead of SNS. In our current U.S. healthcare climate, maintaining the quality of care while also controlling costs is a central objective. We believe that studies like this can contribute to attaining that goal."
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.